Spruce Biosciences (SPRB) closed at $44.55 on November 2, 2026, down 4.0% from the previous close, on volume of 89,984 shares (30-day average 80,616).
Data as of November 2, 2026.
Spruce Biosciences to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference
Business Wire (Mon, 2-Nov 4:05 PM ET)
Russell 2000 estimated to drop 83 stocks in December rebalance - Stephens
Seeking Alpha News (Thu, 29-Oct 3:44 PM ET)
Spruce Biosciences to Participate in the Craig-Hallum Biotech Catalyst Conference
Business Wire (Thu, 15-Oct 4:05 PM ET)
Business Wire (Thu, 8-Oct 4:05 PM ET)
Spruce Biosciences to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
Business Wire (Tue, 8-Sep 4:05 PM ET)
Spruce Biosciences Announces Launch of MPS3BStudy.com
Business Wire (Wed, 26-Aug 8:00 AM ET)
Business Wire (Mon, 24-Aug 8:00 AM ET)
Spruce Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
Business Wire (Wed, 12-Aug 9:00 AM ET)
Business Wire (Wed, 12-Aug 8:00 AM ET)
Spruce Biosciences Appoints Jessica Cohen Pfeffer, M.D., as Vice President, Clinical Development
Business Wire (Mon, 3-Aug 8:00 AM ET)
Spruce Biosciences Inc is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with unmet medical needs. The company develops biologics and small-molecule product candidates aimed at addressing diseases with unmet medical needs and limited or no approved therapies. Its product candidate, TA-ERT for the treatment of Mucopolysaccharidosis Type IIIB (MPS IIIB), is a fusion protein comprised of recombinant human alpha-N-acetylglucosaminidase (rhNAGLU) intended as an enzyme replacement therapy for patients who lack rhNAGLU enzyme activity. TA-ERT is designed to restore rhNAGLU enzyme activity in the central nervous system following intracerebroventricular injection and promote clearance of heparan sulfate in the brain.
Spruce Biosciences trades on the NASDAQ stock market under the symbol SPRB.
As of November 2, 2026, SPRB stock price declined to $44.55 with 89,984 million shares trading.
SPRB has a beta of -0.44, meaning it tends to be less sensitive to market movements. SPRB has a correlation of 0.01 to the broad based SPY ETF.
SPRB has a market cap of $128.04 million. This is considered a Micro Cap stock.
The top ETF exchange traded funds that SPRB belongs to (by Net Assets): VTI, IWM, VXF, IWN, VTWO.
SPRB has underperformed the market in the last year with a return of -58.5%, while SPY returned +11.7%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in SPRB shares. However, SPRB has outperformed the market in the last 3 month and 2 week periods, returning +2.7% and +12.4%, while SPY returned +1.7% and -1.5%, respectively. This indicates SPRB has been having a stronger performance recently.
SPRB support price is $44.17 and resistance is $48.61 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SPRB shares will trade within this expected range on the day.
